Clinical and Biological Prognostic Factors in Follicular Lymphoma

Hematol Oncol Clin North Am. 2020 Aug;34(4):647-662. doi: 10.1016/j.hoc.2020.02.002. Epub 2020 May 6.

Abstract

Follicular lymphoma comprises approximately 20-30% of all cases of B-cell lymphomas. Median survival has improved significantly in the modern era. Prognostic factors include histologic grade, cytogenetics, molecular mutations, the tumor microenvironment, and tumor burden. Clinical prognostic indices are available and increasingly incorporate genetic information. Prognostic factors also arise during the course of treatment. Early progression within 24 months of initial chemoimmunotherapy is an adverse prognostic marker of inferior survival. Other high-risk populations include those with double refractory disease or those with high risk of transformation to diffuse large B-cell lymphoma.

Keywords: Biological risk factors; Clinical risk factors; Follicular lymphoma; Prognostic indices.

Publication types

  • Review

MeSH terms

  • Cell Transformation, Neoplastic
  • Clinical Decision-Making
  • Diagnostic Imaging / methods
  • Disease Management
  • Disease Susceptibility
  • Environment
  • Factor Analysis, Statistical
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Lymphoma, Follicular / diagnosis*
  • Lymphoma, Follicular / etiology
  • Lymphoma, Follicular / mortality*
  • Lymphoma, Follicular / therapy
  • Male
  • Neoplasm Grading
  • Neoplasm Staging
  • Prognosis
  • Tumor Microenvironment